Tesamorelin vs Ipamorelin: The GHRH Analogue and the Ghrelin-Receptor Agonist Compared

Tesamorelin's evidence base is unusual for a research peptide: it includes a positive, adequately powered randomised controlled trial. The pivotal Falutz et al. trial (NEJM, 2007) randomised 412 HIV-infected adults with abdominal lipodystrophy to tesamorelin 2 mg subcutaneous daily or placebo for 26 weeks. Visceral adipose tissue, measured by CT, fell 15.2% in the tesamorelin arm and rose 5.0% on placebo — a statistically significant, clinically meaningful separation for the population studied.^[4]

That trial, together with a pooled phase 3 safety-extension analysis, is what took tesamorelin to an FDA approval: Egrifta in 2010, reformulated as Egrifta SV in 2019, for reducing excess visceral fat specifically in HIV-associated lipodystrophy. A later trial (Stanley et al., 2014) confirmed the visceral-fat effect in a smaller cohort and pointed to a secondary liver-fat signal, later followed up as its own NAFLD endpoint. None of this licenses a broader claim: every one of these trials studied HIV-associated lipodystrophy, a metabolically distinct condition, and extrapolating the roughly 15% figure to general adult body composition is not what the published evidence supports.^[5][6][7][8]

The EU side of that approval is empty. Tesamorelin's marketing-authorisation application was withdrawn in 2012 while the EMA's committee still had open questions, so there is no EPAR and no EU authorisation under any brand. Tesamorelin also belongs to a wider GHRH-analogue family alongside sermorelin and CJC-1295; the three-way comparison covers how those two differ from each other and from tesamorelin in more depth than fits here.^[9]

Ipamorelin's reputation for being 'selective' — releasing GH without moving cortisol or prolactin — comes from a single 1998 study, and it was run in pigs, not people. Conscious swine given ipamorelin showed no rise in ACTH or cortisol even at doses more than 200 times higher than needed for half-maximal GH release, while the older peptides GHRP-6 and GHRP-2 both raised them. That is a real, specific finding. It is also, on its own, an animal finding.^[2]

The human data has not closed that gap. The only published human pharmacokinetic study gave healthy men 15-minute intravenous infusions of ipamorelin and modelled the resulting single-episode GH pulse — a terminal half-life of about 2 hours, peaking near 40 minutes — but it did not report ACTH, cortisol or prolactin at all. The 'clean' endocrine profile ipamorelin is known for is a swine result, not yet a confirmed human one.^[10][2]

Ipamorelin's clinical-trial record is thinner than tesamorelin's, and the one efficacy result that exists is negative. Its human trial targeted post-operative ileus, not growth or body composition: a double-blind, placebo-controlled phase 2 study in 114 adults after bowel resection found a median time to first tolerated meal of 25.3 hours on ipamorelin against 32.6 hours on placebo, a difference that did not reach statistical significance (p = 0.15). A larger, 320-patient follow-on study completed in 2014 has never had results posted to its registry entry.^[11][12]

The table below is a research-context summary, not a ranking — the two molecules were tested for different things in different ways, and the numbers only mean what their study design allows them to mean.^[4][2]

| Attribute | Tesamorelin | Ipamorelin | | --- | --- | --- | | Class | GHRH(1-44) analogue | Ghrelin-receptor (GHS-R1a) agonist, pentapeptide | | Size | 44 amino acids | 5 amino acids | | Reported half-life | ~26 minutes (healthy subjects, subcutaneous, FDA label) | ~2 hours terminal half-life (healthy men, intravenous infusion study) | | Positive human efficacy trial | Yes — visceral fat, HIV-associated lipodystrophy (NEJM, 2007) | No — post-operative ileus trial did not beat placebo (2014) | | FDA status | Approved (Egrifta SV) for HIV-associated lipodystrophy only | Not approved; listed among FDA Category 2 compounding substances | | EMA status | No EPAR; marketing application withdrawn 2012 | No entry in the EMA medicines database | | WADA | Prohibited (S2) | Prohibited (S2.2.4) | | Selectivity / safety data source | Human randomised trials, one indication | Mostly rodent and swine studies |^{[4][5][9][11][13][14][15][10][2]}

Read the half-life row with the study designs in mind: tesamorelin's roughly 26 minutes comes from a subcutaneous-injection FDA label, and ipamorelin's roughly 2 hours comes from an intravenous-infusion pharmacokinetic study. Neither number says anything about which molecule 'works better' — they describe clearance, not efficacy, and they were not measured the same way.^[5][10]

The honest framing is worth stating plainly: this is not a contest with a winner. Tesamorelin and ipamorelin reach the same gland through different doors, and choosing between them as research subjects is choosing which receptor — and which evidence base — the question is actually about.

That logic is also why the catalogue carries a blend pairing a GHRH analogue with a ghrelin-receptor agonist — CJC-1295 and ipamorelin, covered in its own guide — rather than any claim that combining receptors multiplies an effect. The pairing reflects mechanistic coverage for research purposes, not a stacking recommendation.

Both compounds ship lyophilised and require reconstitution before any laboratory use, and each has its own storage-stability window once reconstituted. That detail, and the calculator that goes with it, is handled elsewhere on this site rather than repeated here.